Pharmacopeia News
Most Popular Pharmacopeia Story
Wyeth licenses Pharmacopeia's JAK3 program
Wyeth Pharmaceuticals has struck a development pact involving Pharmacopeia's JAK3 inhibitor program. The program focuses on the activation of T-cells for rheumatoid arthritis, psoriasis and other immunological conditions. Pharmacopeia retains commercialization rights for the treatment of dermatological and ocular diseases via topical administration while Wyeth gains all other rights in exchange for a $5 million upfront payment, up to $9 million in research funds over three years and up to …
Read more...Latest Headlines
- September 25, 2008
- August 5, 2008
- May 30, 2008
- May 16, 2008
- April 11, 2008
- January 10, 2007
- January 3, 2007
- May 24, 2006
- May 22, 2006
- April 12, 2006
- March 29, 2006
- October 25, 2005
- September 28, 2005
- July 11, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
